Vaxart Stock Forecast, Price & News

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

Is Vaxart a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart or view top-rated stocks.

How has Vaxart's stock price been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT stock has increased by 107.7% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Vaxart.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.14). The biotechnology company earned $0.20 million during the quarter, compared to analyst estimates of $0.12 million. Vaxart had a negative trailing twelve-month return on equity of 36.10% and a negative net margin of 5,414.56%. The firm's revenue for the quarter was down 24.5% compared to the same quarter last year.
View Vaxart's earnings history.

When did Vaxart's stock split? How did Vaxart's stock split work?

Shares of Vaxart reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

4 analysts have issued 12 month price objectives for Vaxart's shares. Their forecasts range from $9.00 to $18.00. On average, they anticipate Vaxart's stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 219.8% from the stock's current price.
View analysts' price targets for Vaxart or view top-rated stocks among Wall Street analysts.

Who are Vaxart's key executives?

Vaxart's management team includes the following people:

• Andrei Floroiu, President CEO, CFO & Director
• Sean N. Tucker, Chief Scientific Officer & Senior Vice President (LinkedIn Profile)
• Richard Schwartz, Senior Vice President-Technical Operations
• James F. Cummings, Chief Medical Officer
• Shaily Jaini Garg, SVP-Clinical Development & Project Management

Who are some of Vaxart's key competitors?

Some companies that are related to Vaxart include Adaptive Biotechnologies (ADPT), ImmunityBio (IBRX), Kymera Therapeutics (KYMR), Exscientia (EXAI), Recursion Pharmaceuticals (RXRX), Valneva (VALN), Sana Biotechnology (SANA), Allogene Therapeutics (ALLO), Vericel (VCEL), Revolution Medicines (RVMD), NanoString Technologies (NSTG), Instil Bio (TIL), Atara Biotherapeutics (ATRA), iTeos Therapeutics (ITOS) and Editas Medicine (EDIT).
View all of VXRT's competitors.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), OrganiGram (OGI) and Novan (NOVN).

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kestra Private Wealth Services LLC (0.04%), AE Wealth Management LLC (0.01%), Fi3 FINANCIAL ADVISORS LLC (0.01%), National Bank of Canada FI (0.00%) and Cutler Group LP (0.00%). Company insiders that own Vaxart stock include Armistice Capital, Llc, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

Which major investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Vaxart company stock in the last year include Margaret Echerd, Robert A Yedid, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart or view top insider-selling stocks.

Which major investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Kestra Private Wealth Services LLC, Fi3 FINANCIAL ADVISORS LLC, AE Wealth Management LLC, and National Bank of Canada FI.
View insider buying and selling activity for Vaxart or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $4.30.

How much money does Vaxart make?

Vaxart has a market capitalization of $539.63 million and generates $4.05 million in revenue each year. The biotechnology company earns $-32.22 million in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Vaxart have?

Vaxart employs 28 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

Where are Vaxart's headquarters?

Vaxart is headquartered at 290 Utah Ave. Suite 200, South San Francisco CA, 94080.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500, via email at [email protected], or via fax at 650-871-8580.